Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Conditions: Solid Tumors, Adult; Solid Tumor; Mesothelioma (MPM); Epithelioid Hemangioendothelioma (EHE); NF2 Deficient Mesothelioma; Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes; NF2 Deficiency; YAP1 or TAZ Gene Fusions Intervention: Drug: IK-930 Sponsor: Ikena Oncology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Cancer & Oncology | Genetics | Hemangioendothelioma | Mesothelioma | Research